Market Access

CVS Health is pairing a new Lilly pricing collaboration with a $29 MinuteClinic visit and expanded pharmacist support, disclosed alongside a sharp Q2 earnings beat.

Four pharma commerce experts revisit their 2026 predictions on dealmaking, patient access and commercialization at the year's midpoint.

Gifthealth's Chip Parkinson says direct-to-patient adoption has accelerated since January, driven by structural, not cyclical, market forces.

How commercial trade groups are shifting from distribution execution to strategic partners shaping market access, launch readiness and commercial performance.

Amy Niles of the Patient Advocate Foundation on Medicaid work requirements, ACA subsidy expiration and patient affordability in 2026.

A subtraction-oriented approach to pharmacy data can surface avoidable drug waste that fragmented systems routinely miss.

The models pharma inherited were built for conditions that have changed. A look across the August issue at an industry redesigning itself.

Eli Lilly's acquisition of AtaiBeckley signals growing pharmaceutical industry commitment to psychedelic-based treatments for treatment-resistant depression.

Many barriers to therapy emerge after a prescription is written. Karina Castagna makes the case for access support embedded at the point of care.

Germany's new health insurance law more than doubles mandatory drug rebates. Here is why it matters for US pharma pricing and launches.

RxLogic's Ann Beal on how PBM reform indirectly impacts pharma manufacturers' affordability programs, rebate planning, and patient access.

TailorMed and Tennr are integrating referral automation with medication affordability tools for infusion centers and specialty pharmacies, aiming to address patient barriers earlier.

As Medicare expands GLP-1 access, pharmacies emerge as key to adherence, through patient education, ongoing engagement and timely intervention

Trutakna's FDA approval for IgAN highlights how patient support programs like TRU SUPPORT coordinate access and adoption in specialty drug launches.

Partha Anbil and Partha Khot examine what makes patient support programs succeed, industry adoption trends, key criticisms, and the strategic path forward.

Deanna Horner, EVP of Enterprise DIRECT Strategy at EVERSANA, explains how real-time data generated through direct-to-patient models are shaping pharma's commercial decisions.

In the first half of this analysis, Partha Anbil and Partha Khot examine how patient support programs cut discontinuation and improve patient outcomes, reshaping hub services into an industry standard.

Generating real-world evidence isn't enough. What drives market access is whether payers can actually evaluate and act on it.

Deanna Horner, EVP of Enterprise DIRECT Strategy at EVERSANA, breaks down what's fueling pharma's embrace of direct-to-patient models.

Amber Hussain Siddique explains why that inventory economics, FEFO compliance gaps, and freight cost structures are driving America's persistent drug shortage crisis and what it takes to fix it.

As hub transitions accelerate and digital tools reshape how support is delivered, four patient services experts weigh in on what's driving change in 2026, and what manufacturers need to get right to keep patients on therapy.

Cate Lockhart explains why pharma-generated RWE quality isn't the issue, and how AMCP Standards are closing the communication gap with payers.

As PBM pressure mounts and formulary bidding wars squeeze manufacturers, a direct access marketplace model offers drug makers a path to compete on efficacy, price and real-world outcomes.

AMCP's Cate Lockhart on why only 18% of payers regularly use real-world evidence, and what the new AMCP RWE Standards are doing to change that.

PwC's Philip Sclafani discusses oral GLP-1 cost exposure, oncology drug spend under the medical benefit, and his outlook on PBM reform.